REFERÊNCIAS
  1. Mese H, Matsuo R. Salivary secretion, taste and hyposalivation. J Oral Rehabil. 2007 Oct;34(10):711-23. doi: 10.1111/j.1365-2842.2007.01794.x. PMID: 17824883.
  2. Falcão, D. P., Mota, L. M. H. da, Pires, A. L., & Bezerra, A. C. B. (2013). Sialometria: Aspectos de interesse clínico. Revista Brasileira de Reumatologia, 53(6), 525–531. doi:10.1016/j.rbr.2013.03.001
  3. Abueva C. Photobiomodulation Therapy in the Treatment of Salivary Dysfunction. Medical Lasers 2022;11:15-20. doi.org/10.25289/ML.2022.11.1.15
  4. Proctor GB, Shaalan AM. Disease-Induced Changes in Salivary Gland Function and the Composition of Saliva. Journal of Dental Research. 2021;100(11):1201-1209. doi:10.1177/00220345211004842.
  5. Proctor, G.B., 2016. The physiology of salivary secretion. Periodontol. 2000. https://doi. org/10.1111/prd.12116
  6. de Almeida Padel V, Grégio EM, Machado MA, de Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract. 2008 Mar 1;9(3):72-80. PMID: 18335122.
  7. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc. 2003 Jan;134(1):61-9; quiz 118-9. doi: 10.14219/jada.archive.2003.0018. PMID: 12555958.
  8. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003 Jul;9(4):165-76. doi: 10.1034/j.1601-0825.2003.03967.x. PMID: 12974516.
  9. Turner, M. D. (2016). Hyposalivation and Xerostomia. Dental Clinics of North America, 60(2), 435–443. doi:10.1016/j.cden.2015.11.003
  10. Pedersen, AML, Sørensen, CE, Proctor, GB, Carpenter, GH, Ekström, J. Salivary secretion in health and disease. J Oral Rehabil. 2018; 45: 730–746. https://doi.org/10.1111/joor.12664
  11. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017
  12. Kossioni, A., Kossionis, G. E., & Polychronopoulou, A. (2013). Variation in oral health parameters between older people with and without mental disorders. Special Care in Dentistry, 33(5), 232–238. doi:10.1111/scd.12004
  13. de Ameida PDV, Rodrigues Johann ACB, Azevedo Alanis LR de, de Lima AAS, Trindade Grgio AM. Antidepressants: Side Effects in the Mouth [Internet]. Oral Health Care - Pediatric, Research, Epidemiology and Clinical Practices. InTech; 2012. Available from: http://dx.doi.org/10.5772/37693
  14. Bull, S.A., Hunkeler, E.M., Lee, J.Y., Rowland, C.R., Williamson, T.E., Schwab, J.R., Hurt, S.W., Gonzalez, ´ L., Demers, D., 2002. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann. Pharmacother. https://doi.org/10.1345/aph.1A254.
  15. Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.
  16. Wolff A, Joshi RK, Ekstrom J, Aframian D, Pedersen AML, Proctor G, Narayana N, Villa A, Sia YW, Aliko A, et al. 2017. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D. 17(1):1–28
  17. Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986 Dec;32(6):481-508. doi: 10.2165/00003495-198632060-00002. PMID: 2878798.
  18. Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf. 2004 Sep;3(5):495-504. doi: 10.1517/14740338.3.5.495. PMID: 15335304.
  19. Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM Jr. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun;60(6):389-94. doi: 10.4088/jcp.v60n0608. PMID: 10401918.
  20. Millsop, J. W., Wang, E. A., & Fazel, N. (2017). Etiology, evaluation, and management of xerostomia. Clinics in Dermatology, 35(5), 468–476. doi:10.1016/j.clindermatol.2017.06.010
  21. Genovese WJ. Laser de baixa intensidade: aplicações terapêuticas em odontologia. São Paulo: Editora Santos; 2007
  22. Gonnelli FAS, Palma LF, Giordani AJ, Deboni ALS, Dias RS, Segreto RA, Segreto HRC. Laser de baixa potência para prevenção de hipofluxo salivar em pacientes portadores e câncer de cabeça e pescoço após radioterapia e quimioterapia. Radiol Bras. 2016 Mar/Abr;49(2):86–91.
  23. Saleh J, Figueiredo MA, Cherubini K, Braga-Filho A, Salum FG. Effect of low-level laser therapy on radiotherapy-induced hyposalivation and xerostomia: a pilot study. Photomed Laser Surg. 2014 Oct;32(10):546-52. doi: 10.1089/pho.2014.3741. PMID: 25302460.
  24. Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun, RJJ, Migliorati CA, Lloid CME, Eduardo CP, Walter NF, Marques, MM, Hamdi M (2007) A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15(10):1145–1154. https://doi.org/10.1007/s00520-007-0238-7
  25. Golež, A., Frangež, I., Cankar, K. et al.  Effects of low-level light therapy on xerostomia related to hyposalivation: a systematic review and meta-analysis of clinical trials. Lasers Med Sci  37 , 745–758 (2022). https://doi.org/10.1007/s10103-021-03392-0
  26. Xu, Y., Lin, Y. & Gao, S. Study on the selection of laser wavelengths in the intravascular low-level laser irradiation therapy. Lasers Med Sci 30, 1373–1376 (2015). https://doi.org/10.1007/s10103-015-1732-7
  27. Huang YY, Chen AC, Carroll JD, Hamblin MR (2009) Biphasic dose response in low level light therapy. Dose-response : a publication of International Hormesis Society 7(4):358–383
  28. Sousa, A. S., Silva, J. F., Pavesi, V. C. S., Carvalho, N. A., Ribeiro-Júnior, O., Varellis, M. L. Z., Deana, A. M. (2019). Photobiomodulation and salivary glands: a systematic review. Lasers in Medical Science. doi:10.1007/s10103-019-02914-1
  29. Dompe C, Moncrieff L, Matys J, Grzech-Leśniak K, Kocherova I, Bryja A, Bruska M, Dominiak M, Mozdziak P, Skiba THI, Shibli JA, Angelova Volponi A, Kempisty B, Dyszkiewicz-Konwińska M. Photobiomodulation-Underlying Mechanism and Clinical Applications. J Clin Med. 2020 Jun 3;9(6):1724. doi: 10.3390/jcm9061724. PMID: 32503238; PMCID: PMC7356229.
  30. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Photobiomodulation of human adipose-derived stem cells using 810nm and 980nm lasers operates via different mechanisms of action. Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):441-449. doi: 10.1016/j.bbagen.2016.10.008. Epub 2016 Oct 15. PMID: 27751953; PMCID: PMC5195895
  31. Lončar B, Stipetić MM, Baričević M, Risović D. The effect of low-level laser therapy on salivary glands in patients with xerostomia. Photomed Laser Surg. 2011 Mar;29(3):171-5. doi: 10.1089/pho.2010.2792. Epub 2010 Nov 6. PMID: 21054200.
  32. Fidelix T, Czapkowski A, Azjen S, Andriolo A, Neto PH, Trevisani V (2018) Low-level laser therapy for xerostomia in primary Sjogren’s syndrome: a randomized trial. Internation League of Association for Rheumatology (ILAR) 37(3):729–736. https://doi.org/10.1007/s10067-017-3898-9
  33. Karu T. Photobiology of low-power laser effects. Health physics. 1989;56(5):691-704. Epub 1989/05/01.
  34. Hamblin MR. Photobiomodulation or low-level laser therapy. J Biophotonics. 2016 Dec;9(11-12):1122-1124. doi: 10.1002/jbio.201670113. PMID: 27973730; PMCID: PMC5215795.
  35. Chamusca, FV, Reis S, Lemaire, D, Medrado A. Mediadores do efeito sistêmico do processo inflamatório e terapias fotobiomoduladoras: uma revisão de literatura. Ver Ciências Médicas e Biológicas. 2012;V.11(111):70–8. doi.org/10.9771/cmbio.v11i1.5705
  36. Mikhaylov, V. (2015). The use of Intravenous Laser Blood Irradiation (ILBI) at 630-640 nm to prevent vascular diseases and to increase life expectancy. LASER THERAPY, 24(1), 15–26. doi:10.5978/islsm.15-or-02
  37. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res. 1992 Jul;71(7):1363-9. doi: 10.1177/00220345920710070301. PMID: 1629451.
  38. Vieira KA, Bastos CM, Vitor MGC, Deana AM, Fernandes KPS, Rodrigues MFSD, Pavesi VCS, Bussadori SK. Use of low-level laser therapy on children aged 1 to 5 years with energy-protein malnutrition: A clinical trial. Medicine (Baltimore). 2018 Apr;97(17):e0538. doi: 10.1097/MD.0000000000010538. PMID: 29703031; PMCID: PMC5944562.
  39. Garcia LB, Bulla JR, Kotaka CR, et al. Bacteriological and salivary tests to assess caries risk. Rev bras anal Clin 2009; 41 : 69–76.
  40. Lizarelli, R de FZ. Cordon, R. Bagnato, VS. Cases reports applying vascular systemic photobiomodulation treatment. Revista Científica Multidisciplinar Núcleo do Conhecimento. Year. 08, Ed. 07, Vol. 03, pp. 78-95. July 2023. ISSN: 2448-0959, Access link: https://www.nucleodoconhecimento.com.br/health/vascular-systemic, DOI: 10.32749/nucleodoconhecimento.com.br/health/vascular-systemic
  41. Brzak, B. L., Cigić, L., Baričević, M., Sabol, I., Mravak-Stipetić, M., & Risović, D. (2018). Different Protocols of Photobiomodulation Therapy of Hyposalivation. Photomedicine and Laser Surgery, 36(2), 78–82. doi:10.1089/pho.2017.4325
  42. Plavnik LM, De Crosa ME, Malberti AL (2003) Effect of lowpower radiation (helium/neon) upon submandibulary glands. J Clin Laser Med Surg 21(4):219–225. https://doi.org/10.1089/ 104454703768247792
  43. Oliveira, R. C. R. ., Simonato, L. E. ., & Moreti, L. C. T. . (2022). PACIENTE COM XEROSTOMIA PÓS-COVID-19 EM TRATAMENTO COM LASERTERAPIA: RELATO DE CASO. Revista Ibero-Americana De Humanidades, Ciências E Educação8 (10), 628–642. https://doi.org/10.51891/rease.v8i10.7109